NEAT1 as a prognostic marker and therapeutic target for prostate cancer
This invention relates to diagnosis and prognosis of prostate cancer, as well as therapeutic treatment of prostate cancer. More specifically, the invention provides diagnostic and prognostic methods based on detecting nuclear enriched abundant transcript 1 (NEAT1) levels in a sample. Further provided are methods for treating prostate cancer based on targeting NEAT1 via interfering RNA.
1. A method of determining the presence or risk of developing or advancing prostate cancer in a subject, comprising
providing a predetermined cut off value, wherein the cut off value is selected from the group consisting of NEAT1 long isoform Biochemical recurrence (BCR) endpoint, NEAT1 long isoform Metastatic recurrence (MET) endpoint, NEAT 1 short isoform BCR endpoint, and NEAT 1 short isoform MET endpoint,
detecting the level of NEAT1 in a biological sample from the subject wherein the biological sample contains prostate cells,
comparing the level of said NEAT1 relative to the predetermined cut off value, and
determining the presence or risk of developing or advancing prostate cancer in the subject based on an elevated level of NEAT1 in the sample as compared to the cut off value.
2. The method of claim 1 , wherein said subject has prostate cancer, and an elevated level of NEAT1 as compared to control is indicative of a risk of the cancer progressing into an advanced stage.
3. The method of claim 1 , wherein said subject does not have prostate cancer, and an elevated level of NEAT1 as compared to control is indicative of a risk of developing prostate cancer in the subject.
4. The method of claim 1 , wherein an elevated level of NEAT1 as compared to control is indicative of the presence of prostate cancer in the subject.
5. The method of claim 1 , wherein said sample is selected from the group consisting of prostate tissue, urine, semen, prostatic secretions and prostate cells.
6. The method of claim 1 , wherein said detecting comprising performing an assay selected from Northern blot, RNA ISH, RT-PCR, or RNA Seq.
7. The method of claim 6 , wherein said assay utilizes a nucleic acid primer or probe that hybridizes to a 5′ portion of NEAT1 molecule.
8. The method of claim 6 , wherein said assay is RT-PCR which utilizes a pair of primers, both of which hybridize to a 5′ portion of NEAT1 molecule.
9. A method, comprising
detecting the level of NEAT1 in a biological sample from a subject wherein the biological sample contains prostate cells,
comparing the level of said NEAT1 relative to a predetermined cut off value, and
determining the presence or risk of developing or advancing prostate cancer in the subject based on an elevated level of NEAT1 in the sample as compared to the predetermined cut off value, and
administering to the subject an interfering RNA molecule targeting NEAT1 if the level of NEAT1 in the sample is elevated as compared to the predetermined cut off value.
10. The method of claim 9 , wherein said subject has prostate cancer, and an elevated level of NEAT1 as compared to control is indicative of a risk of the cancer progressing into an advanced stage.
11. The method of claim 9 , wherein said subject does not have prostate cancer, and an elevated level of NEAT1 as compared to control is indicative of a risk of developing prostate cancer in the subject.
12. The method of claim 9 , wherein an elevated level of NEAT1 as compared to control is indicative of the presence of prostate cancer in the subject.
13. The method of claim 9 , wherein said sample is selected from the group consisting of prostate tissue, urine, semen, prostatic secretions and prostate cells.
14. The method of claim 9 , wherein said detecting comprising performing an assay selected from Northern blot, RNA ISH, RT-PCR, or RNA Seq.
15. The method of claim 14 , wherein said assay utilizes a nucleic acid primer or probe that hybridizes to a 5′ portion of NEAT1 molecule.
16. The method of claim 14 , wherein said assay is RT-PCR which utilizes a pair of primers, both of which hybridize to a 5′ portion of NEAT1 molecule.
17. The method of claim 9 , wherein the interfering RNA molecule is an siRNA.
18. The method of claim 9 , wherein the interfering RNA molecule is an shRNA.
19. The method of claim 17 , wherein the siRNA is conjugated with nanoparticles.
20. The method of claim 17 , wherein the siRNA is conjugated with PAMAM dendrimers.
21. The method of claim 9 , wherein the subject exhibits resistance to therapy targeting androgen-receptor mediated functions.
22. The method of claim 9 , wherein the patient has an advanced stage prostate cancer.
23. The method of claim 9 , wherein the interfering RNA is administered to said patient in combination with a therapy targeting androgen-receptor mediated functions.
24. The method of claim 9 , wherein the cut off value is selected from the group consisting of NEAT1 long isoform Biochemical recurrence (BCR) endpoint, NEAT1 long isoform Metastatic recurrence (MET) endpoint, NEAT 1 short isoform BCR endpoint, and NEAT 1 short isoform MET endpoint.